(Q46952308)

26 December 2017

title

The role of fenofibrate in clinical practice (English)

1 reference

26 December 2017

author name string

Alberto Zambon

series ordinal

1

1 reference

26 December 2017

Kenneth Cusi

series ordinal

2

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

26 December 2017

Diabetes and Vascular Disease Research

published in

1 reference

26 December 2017

volume

4 Suppl 3

1 reference

26 December 2017

page(s)

S15-20

1 reference

26 December 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Characteristics of US adults with the metabolic syndrome and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Current overview of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Risk of adverse events with fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.053

21 January 2018

Identifiers

DOI

10.3132/DVDR.2007.053

1 reference

26 December 2017

1 reference

26 December 2017